ABBV-3373

• UNSPSC Description:

  ABBV-3373 is an anti-TNF antibody drug conjugate (ADC). ABBV-3373 is composed of the humanized antibody Adalimumab (HY-P9908) conjugated with a glucocorticoid receptor modulator (HY-148436). ABBV-3373 can be used in the study of rheumatoid arthritis[1].

• Target Antigen:

  Antibody-Drug Conjugates (ADCs); Glucocorticoid Receptor; TNF Receptor

• Type:

  Reference compound

• Related Pathways:

  Antibody-drug Conjugate/ADC Related;Apoptosis;Immunology/Inflammation;Vitamin D Related/Nuclear Receptor

• Applications:

  COVID-19-immunoregulation

• Field of Research:

  Inflammation/Immunology

• Assay Protocol:

  https://www.medchemexpress.com/abbv-3373.html

• Smiles:

  [ABBV-3373]

• References & Citations:

  [1]Qu P, et al. Discovery of ABBV-3373, an Anti-TNF Glucocorticoid Receptor Modulator Immunology Antibody Drug Conjugate. J Med Chem. 2022 Dec 8;65(23):15893-15934.

• Shipping Conditions:

  Room temperature

• Clinical Information:

  Phase 2